Australia’s competition regulator seeks to appeal Pfizer judgment
26-06-2018
MarkRubens / iStockphoto.com
A court has rejected an appeal by the Australian Competition and Consumer Commission (ACCC), in a decision which confirmed that deals made by Pfizer in relation to generic cholesterol-lowering medication do not constitute a misuse of its market power.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer, Federal Court of Australia, ACCC, atorvastatin, Lipitor, patent expiry, anti-competition, market competition, generic competition, drug sales
